

Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer

Information for the public

Published: 2 March 2026

www.nice.org.uk

Durvalumab (Imfinzi) is available on the NHS. It is a possible treatment for bladder cancer that has spread into the muscle layer of the bladder in adults, and is used:

- with gemcitabine and cisplatin before surgery (neoadjuvant treatment), then
- alone after surgery (adjuvant treatment).

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on bladder cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Fight Bladder Cancer](#), 01844 351621
- [Action Bladder Cancer](#), 0300 302 0085
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-9325-3